High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

被引：0
|
作者：
Farag, Sarah
Bacher, Ulrike
Legros, Myriam
Betticher, Daniel
Luthi, Jean-Marc
Egger, Thomas
Zander, Thilo
Jeker, Barbara
Pabst, Thomas
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141545
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Idarubicin, melphalan and cyclophosphamide:: an intensified high-dose regimen for the treatment of myeloma patients
    Heyll, A
    Söhngen, D
    Kobbe, G
    Schneider, P
    Bauser, U
    Thiele, KP
    Wehmeier, A
    Südhoff, T
    Quenzel, EM
    Rieth, C
    Wernet, P
    Fischer, J
    Frick, M
    Aul, C
    LEUKEMIA, 1997, 11 : S32 - S34
  • [22] Change in antiemetic prophylaxis in patients with myeloma undergoing conditioning with high-dose melphalan
    Skagerlind, L.
    Liljeholm, M.
    Astrom, F.
    Lindkvist, U.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S491 - S491
  • [23] Neoplasias after high-dose melphalan for multiple myeloma (MM) patients (pts)
    da Costa, F. Leal
    Miranda, N.
    Coelho, J. L. Passos
    Guimaraes, A.
    Ferreira, I.
    Teixeira, G.
    Fernandez, E.
    Abecasis, M. M.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S443 - S443
  • [24] HIGH-DOSE MELPHALAN IS A SAFE CONDITIONING REGIMEN IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Cangini, D.
    Cerchione, C.
    Giannini, M. B.
    Di Battista, V.
    Frabetti, F.
    Petracci, E.
    Ronconi, S.
    Martinelli, G.
    HAEMATOLOGICA, 2019, 104 : 163 - 163
  • [25] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BONE MARROW TRANSPLANTATION, 2018, 53 : 262 - 263
  • [26] Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
    Palumbo, A
    Bringhen, S
    Coravito, T
    Merla, E
    Capporella, V
    Callea, V
    Cangialosi, C
    Grasso, M
    Rossini, F
    Galli, M
    Catalano, L
    Zamagni, E
    Petrucci, MT
    De Stefano, V
    Ceccarelli, M
    Ambrosini, MT
    Avonto, I
    Falco, P
    Ciccone, G
    Liberati, AM
    Musto, P
    Boccadoro, M
    LANCET, 2006, 367 (9513): : 825 - 831
  • [27] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
  • [28] METASTATIC CARCINOMA OF THE PENIS - COMPLETE REMISSION AFTER HIGH-DOSE METHOTREXATE CHEMOTHERAPY
    GARNICK, MB
    SKARIN, AT
    STEELE, GD
    JOURNAL OF UROLOGY, 1979, 122 (02): : 265 - 266
  • [29] Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
    C Dumontet
    S Landi
    T Reiman
    T Perry
    A Plesa
    I Bellini
    R Barale
    L M Pilarski
    J Troncy
    S Tavtigian
    F Gemignani
    Bone Marrow Transplantation, 2010, 45 : 1316 - 1324
  • [30] Feasibility of administering high-dose melphalan (HDM) with autotransplantation in myeloma patients on dialysis.
    Sirohi, B
    Powles, R
    Kulkarni, S
    Menon, A
    Ahmed, T
    Saso, R
    Goyal, S
    Rudin, C
    Treleaven, J
    BLOOD, 2001, 98 (11) : 399B - 399B
12345